Abbott D2E7 Patient Rollover From Access Program Will Follow Kaletra Model
Executive Summary
Abbott will use its experience from the Kaletra launch to convert rheumatoid arthritis patients out of D2E7's patient access program and onto paid drug following the expected 2003 approval of the tumor necrosis factor inhibitor